On 28 November 2024, a General Assembly meeting of stakeholders of the Latvian Medicines Verification Organisation (LZVO) was held. At this meeting, the strategy for the coming years and the budget for 2025 were approved.
The General Assembly also approved the fixed annual fee for 2025 for the marketing authorisation holders (MAHs), including parallel importers and parallel distributors of medicines in the territory of Latvia, in accordance with the financing policy for the maintenance and development of the Latvian Medicines Verification System.
On 29 November, in the closed section of the customer portal, LZVO informed all MAH contacts about the fixed annual fee for the upcoming year.
MAH representatives are invited to contact LZVO at info@lzvo.lv for any questions concerning the annual fee or other current events.